Eupraxia Pharmaceuticals Inc.

Developing Precision Therapies

Add To Watchlist
General Information
Company Name
Eupraxia Pharmaceuticals Inc.
Founded Year
2012
Location (Offices)
Canada +2
Founders / Decision Makers
James Helliwell - Chief Executive Officer Paul Brennan - Chief Business Officer Mark Kowalski - Chief Medical Officer Amanda Malone - Chief Operating Officer and Chief Scientific Officer, Chief Scientific Officer
Number of Employees
36
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Eupraxia Pharmaceuticals Inc. - Company Profile

Eupraxia Pharmaceuticals Inc.

Slogan: Developing Precision Therapies

Description: Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia’s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

Founded: 2012

Industries: Biotechnology, Health Care, Pharmaceutical

Headquarter: Canada

Last Investment: $33.87M Post-IPO Equity investment at 12 March 2024

Last Investment Investors: Not disclosed

Taxonomy: clinical-stage, drug development, precision therapies, extended-release formulations, therapeutic areas, unmet medical needs, patient benefit, long-acting formulations, post-surgical pain, infections, tolerability, osteoarthritis, veterinary medicine, animal health

Funding Rounds & Investors of Eupraxia Pharmaceuticals Inc. (5)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $33.87M - 12 Mar 2024
Post-IPO Equity $20.00M - 04 Aug 2023
Post-IPO Equity $14.70M - 20 Apr 2022
Post-IPO Debt $10.00M 1 Silicon Valley Bank 21 Jun 2021
Angel Round Unknown - 21 Dec 2012

Latest News of Eupraxia Pharmaceuticals Inc.

View All

No recent news or press coverage available for Eupraxia Pharmaceuticals Inc..

Similar Companies to Eupraxia Pharmaceuticals Inc.

View All
Eupraxia Pharmaceuticals Inc. - Similar company to Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. Developing Precision Therapies
Argo Biopharma - Similar company to Eupraxia Pharmaceuticals Inc.
Argo Biopharma Committed to developing a new generation of siRNA drugs to provide better treatments for global patients.
Concert Pharmaceuticals, Inc. - Similar company to Eupraxia Pharmaceuticals Inc.
Concert Pharmaceuticals, Inc. Creating New Possibilities for Patients to Live Their Lives
XenoPort, Inc. - Similar company to Eupraxia Pharmaceuticals Inc.
XenoPort, Inc.
Imugene Limited - Similar company to Eupraxia Pharmaceuticals Inc.
Imugene Limited Bringing Effective New Treatments And Options To Patients Who Need Them
Circle Decoration Circle Decoration

Want to dive deeper into Eupraxia Pharmaceuticals Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now